SCORAD — Atopic Dermatitis Severity Calculator

About the SCORAD — Atopic Dermatitis Severity Calculator

The Scoring Atopic Dermatitis (SCORAD) index is the most widely used clinical tool for assessing the severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis, it combines three components: disease extent (percentage of body surface area affected), clinical intensity (six observable signs), and subjective symptoms (pruritus and sleep disturbance).

The SCORAD formula — A/5 + 7B/2 + C — weights intensity most heavily (maximum 63 points from the B component), reflecting the clinical importance of lesion severity. Scores range from 0 to 103, classified as mild (< 25), moderate (25–50), or severe (> 50). This three-category classification directly maps to treatment algorithms in international guidelines (EAACI, AAD, BAD).

In clinical practice, SCORAD is used for initial severity assessment, treatment step selection, disease monitoring over time, clinical trial endpoints, and insurance pre-authorization for biologic therapies. The Objective SCORAD (excluding subjective symptoms) is preferred in research settings where patient-reported outcomes may introduce variability.

When This Page Helps

SCORAD is useful when disease severity needs to be described in a reproducible way rather than as a loose impression. It keeps extent, visible inflammation, and symptom burden on the same scale so eczema severity can be tracked over time or discussed consistently across visits.

How to Use the Inputs

1. Estimate the percentage of body surface area affected in each region using the rule of 9s.
2. Rate each of the six intensity criteria (erythema, edema, oozing, excoriation, lichenification, dryness) from 0-3.
3. Have the patient rate pruritus and sleep disruption on 0-10 visual analog scales.
4. Review the total SCORAD, objective SCORAD, severity classification, and treatment recommendation.
5. Use the component breakdown to identify which aspect (extent, intensity, or symptoms) is driving severity.
6. Track SCORAD over serial visits to monitor treatment response — a decrease of 8.7 points is clinically meaningful.

Example Calculation

Tips & Best Practices

• Assess SCORAD before and after treatment changes — this creates an objective treatment response record.
• Evaluate intensity on the most representative affected area, not the worst or mildest spot.
• The rule of 9s for extent: head 9%, each arm 9%, each leg 18%, anterior trunk 18%, posterior trunk 18%, genitals 1%.
• For clinical trials, use Objective SCORAD (without pruritus and sleep scores) to eliminate patient reporting variability.
• In practice, track the individual components separately — a patient may improve in extent but worsen in intensity, requiring therapy adjustment.

Why SCORAD Has Three Parts

SCORAD combines how much skin is involved, how inflamed the lesions look, and how disruptive the symptoms feel to the patient. That three-part structure is why it can look different from purely clinician-scored tools such as EASI.

Why the Objective Score Is Still Useful

Separating the objective component can help when itch and sleep loss fluctuate for reasons that are not fully visible on the skin exam. Looking at both numbers together often gives a clearer picture than using either one alone.

Best Use of the Result

The score is most helpful for serial follow-up, trial-style documentation, and communicating severity in a consistent way. It works best when it supports the clinical review instead of being treated as the entire treatment decision.

Frequently Asked Questions

• How does SCORAD differ from EASI?

  SCORAD includes subjective symptoms (pruritus, sleep loss) while EASI (Eczema Area and Severity Index) is entirely clinician-assessed. EASI is more commonly used in clinical trials; SCORAD is more common in clinical practice because it captures patient experience. Both are validated.

• What is the MCID for SCORAD?

  The Minimal Clinically Important Difference (MCID) for SCORAD is approximately 8.7 points. A decrease of this magnitude represents a meaningful improvement that patients and clinicians can perceive. For Objective SCORAD, the MCID is approximately 6.6 points.

• Why is intensity weighted so heavily?

  The B component (intensity) can contribute up to 63 of the maximum 103 points because clinical lesion severity most directly impacts treatment decisions. A patient with 10% BSA involvement but severe oozing and excoriation needs more aggressive treatment than someone with 30% BSA of mild dryness.

• How do I assess dryness in SCORAD?

  Dryness is assessed on uninvolved (non-lesional) skin only, as involved skin may have multiple overlapping signs. Rate dryness 0-3 on typical unaffected skin: 0 = normal, 1 = slight roughness, 2 = rough with visible scaling, 3 = severe cracking.

• Should I use SCORAD for children?

  Yes, but the visual analog scales (pruritus, sleep loss) can be challenging for young children. Parents can report on behalf of children under 7. For infants, clinician-assessed scores (Objective SCORAD) may be more reliable.

• What SCORAD change justifies escalating treatment?

  A SCORAD increase of > 8.7 points (the MCID) on current therapy suggests treatment failure. Persistent SCORAD ≥ 50 despite moderate-potency topical therapy or SCORAD ≥ 25 despite optimal topical management may warrant systemic therapy consideration.